公开(公告)号：NZ622112A

公开(公告)日：2016-07-29

申请号：NZ62211212

申请日：2012-09-07

Applicant: PHARMACYCLICS INC

Inventor： KLOOS IOANA ,  ROBERT RENATA ,  JACQUET-BESCOND ANNE ,  DEPIL STÉPHANE ,  CHENEL MARYLORE ,  FOULIARD SYLVAIN ,  BALASUBRAMANIAN SRIRAM

IPC: A61K31/138 ,  A61K31/343 ,  A61K31/704 ,  A61K33/24 ,  A61P35/00

Abstract: Disclosed herein is the use of the compound of formula I N-hydroxy-4-{ 2-[3-{ N,N-dimethylaminomethyl)benzofuran-2-ylcarbonyl­amino]ethoxy} benzamide (abexinostat/PCI-24781): or an addition salt thereof with a pharmaceutically acceptable acid or base in the manufacture of a medicament for use in the treatment of cancer wherein the medicament is to be administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), in a human patient in need thereof. Also disclosed is the use in combination with a surgical, chemotherapy or hormone therapy treatment or with radiotherapy, wherein the chemotherapy treatment is not FOLFOX.

公开(公告)号：SG11201400120UA

公开(公告)日：2014-09-26

申请号：SG11201400120U

申请日：2012-09-07

Applicant: SERVIER LAB ,  PHARMACYCLICS INC

Inventor： KLOOS IOANA ,  ROBERT RENATA ,  JACQUET-BESCOND ANNE ,  DEPIL STÉPHANE ,  CHENEL MARYLORE ,  FOULIARD SYLVAIN ,  BALASUBRAMANIAN SRIRAM

IPC: A61K31/138 ,  A61K31/343 ,  A61K31/704 ,  A61K33/24 ,  A61P35/00

Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.

公开(公告)号：HK1201150A1

公开(公告)日：2015-08-28

申请号：HK14112851

申请日：2014-12-23

Applicant: PHARMACYCLICS INC

Inventor： KLOOS IOANA ,  ROBERT RENATA ,  JACQUET-BESCOND ANNE ,  DEPIL STPHANE ,  CHENEL MARYLORE ,  FOULIARD SYLVAIN ,  BALASUBRAMANIAN SRIRAM

IPC: A61K20060101 ,  A61P20060101

Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.

公开(公告)号：CA2847011A1

公开(公告)日：2013-03-14

申请号：CA2847011

申请日：2012-09-07

Applicant: SERVIER LAB ,  PHARMACYCLICS INC

Inventor： KLOOS IOANA ,  ROBERT RENATA ,  JACQUET-BESCOND ANNE ,  DEPIL STEPHANE ,  CHENEL MARYLORE ,  FOULIARD SYLVAIN ,  BALASUBRAMANIAN SRIRAM

IPC: A61K31/138 ,  A61K31/343 ,  A61K31/704 ,  A61K33/24 ,  A61P35/00

Abstract: NOUVEAU SCHEMA D'ADMINISTRATION DU W-HYDROXY-4-{2-[3-(W,W-DIMETHYLAMINOMETHYL)BENZOFU- RAN-2-YLCARBONYLAMINO]ETHOXY} BENZAMIDE /V-hydroxy-4-{2-[3-{/V,/V-diméthylaminométhyl)benzofu- ran-2-ylcarbonylamino]éthoxy} benzamide de formule (I) : ou un de ses sels d'addition à un acide ou à une base pharmaceutiquement acceptable, seul ou en association avec un traitement de chirurgie, de chimiothérapie, d'hormonothérapie ou avec la radiothérapie, pour le traitement du cancer, caractérisé en ce qu'il est administré pendant 4 jours consécutifs, cette période étant suivie de 3 jours consécutifs sans aucune administration du composé de formule (I), étant entendu que le traitement de chimiothérapie n'est pas le FOLFOX.

公开(公告)号：SG10201505619QA

公开(公告)日：2015-08-28

申请号：SG10201505619Q

申请日：2012-09-07

Applicant: PHARMACYCLICS INC

Inventor： KLOOS IOANA ,  ROBERT RENATA ,  JACQUET-BESCOND ANNE ,  DEPIL STÉPHANE ,  CHENEL MARYLORE ,  FOULIARD SYLVAIN ,  BALASUBRAMANIAN SRIRAM

Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.

公开(公告)号：ZA201401710B

公开(公告)日：2015-01-28

申请号：ZA201401710

申请日：2014-03-07

Applicant: LES LABORATORIES SERVIER ,  PHARMACYCLICS INC

Inventor： KLOOS IOANA ,  JACQUET-BESCOND ANNE ,  CHENEL MARYLORE ,  BALASUBRAMANIAN SRIRAM ,  ROBERT RENATA ,  DEPIL STEPHANE ,  FOULIARD SYLVAIN

IPC: A61K20060101 ,  A61P20060101

Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.

公开(公告)号：AR087029A1

公开(公告)日：2014-02-05

申请号：ARP120102390

申请日：2012-07-02

Applicant: SERVIER LAB ,  PHARMACYCLICS INC

Inventor： DEPIL STEPHANE ,  JACQUET-BESCOND ANNE ,  KLOOS IOANA ,  SARRY ANNE ,  LAURE-BALASUBRAMANIAN SRIRAM ,  BUGGY JOSEPH

IPC: A61K31/343 ,  A61K31/19 ,  A61K31/282 ,  A61K31/513 ,  A61K31/519 ,  A61P35/00

Abstract: Asociación entra la N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonil-amino]etoxi}benzamida de fórmula (1), o una de sus sales de adición a un ácido o a una base farmacéuticamente aceptable y el FOLFOX. Medicamentos.Reivindicación 2: Asociación según la reivindicación 1 caracterizada porque la N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida se utiliza en la forma de un hidrocloruro. Reivindicación 7: Asociación según una de las reivindicaciones 4 a 6 caracterizada porque los compuestos de la asociación se administran durante 5 días consecutivos, estando seguido este periodo de 9 días consecutivos sin ninguna administración. Reivindicación 8: Asociación según una de las reivindicaciones 4 a 6 caracterizada porque la N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida se administra durante 4 días consecutivos, mientras que el FOLFOX se administra del tercer al quinto día. Reivindicación 9: Asociación según una de las reivindicaciones 4 a 6 caracterizada porque la N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida se administra durante 4 días consecutivos, mientras que el oxaliplatino y el ácido folínico se administran simultáneamente el tercer día, infusión al cabo de la cual se administra el 5-fluorouracilo de manera continua hasta el quinto día.

公开(公告)号：UY34533A

公开(公告)日：2013-06-28

申请号：UY34533

申请日：2012-12-19

Applicant: SERVIER LAB ,  PHARMACYCLICS INC

Inventor： JACQUET-BESCOND ANNE ,  IOANA KLOOS ,  DEPIL STEPHANE ,  BENJAMIN VERILLAUD ,  KRAUS-BERTHIER LAURENCE ,  PIERRE BUSSON

IPC: C07D307/78 ,  A61K31/282 ,  A61K31/343 ,  A61N5/00 ,  A61P35/00

Abstract: N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida de fórmula (I)o una de sus sales de adición a un ácido o a una base farmacéuticamente aceptable, en asociación con un tratamiento de quimioterapia o con radioterapia para su utilización en el tratamiento del carcinoma de nasofaringe. Medicamentos.

公开(公告)号：AU2016202594A1

公开(公告)日：2016-05-19

申请号：AU2016202594

申请日：2016-04-22

Applicant: PHARMACYCLICS INC

Inventor： KLOOS IOANA ,  ROBERT RENATA ,  JACQUET-BESCOND ANNE ,  DEPIL STEPHANE ,  CHENEL MARYLORE ,  FOULIARD SYLVAIN ,  BALASUBRAMANIAN SRIRAM

IPC: A61K31/138 ,  A61K31/343 ,  A61K31/704 ,  A61K33/24 ,  A61P35/00

Abstract: NEW ADMINISTRATION REGIME FOR N-HYDROXY-4-{2-[3-(N,N-DIMETHYLAMINOMETHYL)BENZOFURAN-2 YLCARBONYLAMINO]ETHOXY}BENZAMIDE N-hydroxy-4-12-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy} benzamide of formula (I): H(J _0 =0 or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with a surgery, chemotherapy, hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that chemotherapy is not FOLFOX. Medicaments are also disclosed.

公开(公告)号：HK1203484A1

公开(公告)日：2015-10-30

申请号：HK15103406

申请日：2015-04-08

Applicant: PHARMACYCLICS INC

Inventor： DEPIL STPHANE ,  JACQUET-BESCOND ANNE ,  KLOOS IOANA ,  SARRY ANNE-LAURE ,  BALASUBRAMANIAN SRIRAM ,  BUGGY JOSEPH

IPC: C07D20060101 ,  A61K20060101

Abstract: Association between N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-yl-carbonylamino]ethoxy}benzamide of formula (I): an addition salt thereof with a pharmaceutically acceptable acid or base, and FOLFOX. Medicaments.